News Article | May 24, 2017
— Ulcerative Colitis - Pipeline Review, H1 2017 market research report adds on ReportsnReports.com store. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse Ulcerative Colitis Pipeline report has 85 Company Profiles, 121 Tables and 11 Figures, Spread across 409 Pages Report Available at http://www.reportsnreports.com/reports/992899-ulcerative-colitis-pipeline-review-h1-2017.html . Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids. Main key players of Ulcerative Colitis are 4D Pharma PLC, AbbVie Inc, AbGenomics International Inc, Abivax SA, Adello Biologics LLC, Advinus Therapeutics Ltd, Aerpio Therapeutics Inc, Akebia Therapeutics Inc, Allergan Plc, Am-Pharma BV, Amgen Inc, Aptevo Therapeutics Inc, Arena Pharmaceuticals Inc, Atlantic Bio Sci LLC, Atlantic Healthcare Plc, Blueberry Therapeutics Ltd, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, ChemoCentryx Inc, ChironWells GmbH, Circle33 LLC, Coherus BioSciences Inc, Cosmo Pharmaceuticals NV, Dr. August Wolff GmbH & Co KG Arzneimittle, Dr. Falk Pharma GmbH, EA Pharma Co Ltd, Eli Lilly and Company, Enceladus Pharmaceuticals BV, Enterome Bioscience SA, Ferring International Center SA, Galapagos NV, Genentech Inc, Genor BioPharma Co Ltd more.. Discount Available at http://www.reportsnreports.com/contacts/discount.aspx?name=992899 (This report is available at upto 25% Discount till June 02nd 2017.) Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Ulcerative Colitis – Pipeline market report provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Order a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=992899 Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal). • The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) Table of Contents: Table of Contents Introduction Ulcerative Colitis - Overview Ulcerative Colitis - Therapeutics Development Ulcerative Colitis - Therapeutics Assessment Ulcerative Colitis - Companies Involved in Therapeutics Development Ulcerative Colitis - Drug Profiles Ulcerative Colitis - Dormant Projects Ulcerative Colitis - Discontinued Products Ulcerative Colitis - Product Development Milestones Appendix 3 About Us: ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details at firstname.lastname@example.org and we would be happy to help you find the business intelligence that you need. ReportsnReports.com offers research studies on agriculture, energy and power, automotive, Semiconductor and Electronics, Manufacturing & Construction, chemicals, environment, medical devices, healthcare, food and beverages, water and much more. For more information, please visit http://www.reportsnreports.com/reports/992899-ulcerative-colitis-pipeline-review-h1-2017.html
Ferring International Center S.A. | Date: 2012-10-03
The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for the treatment of prostate cancer in a subject who is at risk for cardiovascular disease.
Ferring International Center Sa | Date: 2014-11-14
Ferring International Center S.A. | Date: 2014-11-05
The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for the treatment of prostate cancer.
Ferring International Center S.A. | Date: 2011-07-06
Disclosed are improved granular pharmaceutical preparations, together with improved methods and apparatus for preparation of granules for use in such preparations. Such methods are especially useful for making granules for solid oral dose pharmaceutical preparations, and are particularly suited to the production of granules comprising 5-aminosalicylic acid (5-ASA) for the treatment of inflammatory bowel disease. The granules exhibit a more sharply peaked length distribution, and hence aspect ratio distribution, and have a consequently much sharper dissolution profile after further processing.
Ferring International Center S.A. | Date: 2013-10-16
Compositions comprising degarelix for the treatment of metastatic stage prostate cancer in a subject are provided.
Ferring International Center SA | Date: 2016-08-16
Ferring International Center S.A. | Date: 2013-12-20
Ferring International Center S.A. | Date: 2014-11-17
The use of a dopamine agonist in the manufacture of a medicament for the treatment or prevention of endometriosis.
Ferring International Center S.A. | Date: 2011-09-27
A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavor; products, intermediate products, and uses thereof.